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Abstract
The regulation of mediator release in human intestinal mast cells is largely unknown. Apart from IgE receptor crosslinking no secretagogues have been described so far. This study examined the effect of two cytokines (c-kit ligand and interleukin 3) and other agonists on human intestinal mast cell function. Cells were isolated from surgery specimens of 47 patients undergoing intestinal resection because of tumours or inflammatory bowel disease. Cell suspensions contained 3/6% mast cells (mean of 50 experiments).
After preincubation without or with c-kit ligand or interleukin 3, cells were stimulated by IgE receptor crosslinking, C5a or formyl-methionyl-leucyl-phenylalanine (fMLP). Histamine and sulphidoleukotriene release was measured in supernatants. The sequential stimulation of the cells with c-kit ligand and IgE receptor crosshinking induced the release of high amounts of histamine and leukotrienes, whereas each agonist by itself induced only marginal mediator release. Interleukin 3 induced no release by itself, but enhanced the IgE receptor dependent release, possibly by an indirect mechanism. No significant mediator release was seen in response to C5a and fMLP, even if the cells were pretreated with c-kit ligand. The mediator release, particularly that of leukotrienes, was higher in cells isolated from actively inflamed tissue from patients with inflammatory bowel disease compared with controls. In conclusion, it was found that, apart from IgE receptor crosslinking, c-kit ligand and interleukin 3 regulate mediator release in human intestinal mast cells. The enhancement of mediator release by cytokines may be of particular relevance in the pathogenesis ofinflammatory bowel diseases and food intolerance reactions. (Gut 1996; 38: 104-114) Keywords: mast cells, histamine release, c-kit ligand, interleukin 3, inflammatory bowel disease.
Human mast cells are characterised by metachromatic cytoplasmic granules containing proteoglycans, histamine, and proteases, and by the high affinity IgE receptor on their cellular surface.1-3 They are typically located in close association with tissue forming barriers such as the skin, mucosa, and submucosa of the gastrointestinal and the respiratory tract, and blood vessels, but also in muscular organs such as the heart and the uterus. Mast cells exert biological effects by releasing preformed mediators stored in the granules and de novo synthesised mediators such as leukotrienes, prostaglandins, and cytokines.3 4 The role of human mast cells in mediating allergic reactions is well known. In addition, there is increasing evidence that mast cells participate in chronic inflammatory processes such as delayed type hypersensitivities, fibrosis, and neuroimmunological disorders. [1] [2] [3] [4] [5] Other studies suggest that mast cells not only exert proinflammatory effects but also participate in regulating repair processes such as wound healing and tissue remodelling.3 6 However, the pathophysiological role of mast cells in the human intestinal tract is largely unknown. Some studies indicate that intestinal mast cells may participate in food hypersensitivity reactions and other diseases such as inflammatory bowel disease.7-14 The significant occurrence of this cell type in the gut and the broad spectrum of activities of mast cell derived mediators suggests that this cell type could play a particular part in physiology and pathophysiology of the intestinal tract.
The regulation of mast cell activation is poorly understood. Apart from IgE receptor crosslinking by allergen or in vitro by IgE receptor antibodies, no triggers for mediator release have been described for human mucosal mast cells of the lung or the intestine.2 3 In contrast, human skin mast cells can be triggered for mediator release by IgE dependent and IgE independent stimuli such as the anaphylatoxin C5a and the neuropeptide substance p. '5 Rat peritoneal mast cells release histamine in response to nerve growth factor, interleukin 3 (IL 3) , and substance p.' 2 However, human lung and skin mast cells do not release mediators in response to nerve growth factor and substance P, and they lack the IL 3 receptor,16 17 Recently, a novel growth factor named stem cell factor or c-kit ligand has been identified in rodents and humans.21 C-kit ligand binds to the proto-oncogene c-kit and acts as a growth factor on bone marrow progenitor cells in synergism with IL 3, G-CSF, GM-CSF, and erythropoietin. In particular, it promotes the development of mast cells from CD34+ stem cells in vitro and in vivo. Apart from its role as a growth factor for mast cells and other bone marrow derived cell lineages, the biological relevance of c-kit ligand is poorly understood. In previous studies, we showed that c-kit ligand strongly modulates the function of mature human lung mast cells. 16 (Fig 4 (B) ). The experiments show a strong correlation between the mediator release in response to mAb 29C6 alone and mAb 29C6 after c-kit ligand preincubation (r=072 and 0 93 for histamine and leukotriene release, respectively; Fig 4 (C) and (D) . The correlation was slightly weaker between the release by c-kit ligand+mAb 29C6 and receptor independent ionomycin (Fig 4 (E) and (F) (p<005) and for leukotriene productio either spontaneous release (p<0 05) or aft stimulation with c-kit ligand and mAb 29C (p<005) or with ionomycin (p<0.01). three patients with Crohn's disease, bo inflamed and macroscopically normal tissi could be obtained. Interestingly, the relea reaction was much more pronounced in ce derived from inflamed areas than in cells fro uninflamed areas suggesting an associati between the release reaction and the activi of the disease (data not shown). In gener. there was a tendency to higher release in ma cells from patients with inflammatory bow disease compared with controls (patients wi intestinal tumours or other diseases). Expression of c-kit in intestinal tissue Table III shows that in patients with inflammatory bowel disease the number of tryptase positive and c-kit positive lamina propria mast cells is slightly enhanced in areas of macroscopically normal mucosa compared with controls. By contrast, mast cell numbers tended to be lower in areas of active inflammation, the differences were not statistically significant (analysis of variances, p>0 05). The number of tryptase positive and c-kit positive mast cells were highly correlated (r=0.79, p<000 1, n= 52), but the ratio of c-kit/tryptase positive cells did not differ between the patient groups. The histological results were almost identical in patients with Crohn's disease and ulcerative colitis (not shown).
Discussion
In this study functionally intact human mast cells were isolated from normal and pathologically changed intestinal tissue. Despite the extensive cell isolation procedure of five hours, most of the cell preparations were viable as shown by Trypan blue staining. In more than three of four experiments, histamine release could be measured, and in about one of two experiments sulphidoleukotriene production was detectable. The number of experiments, however, in which no mediators could be measured was larger than expected from similar release experiments performed with peripheral blood leucocytes.18-20 Such negative results may be caused by low cell numbers or and by the isolation procedure, which is pare ticularly extensive and complicated for the isolation of human intestinal mast cells. Cells may be damaged during the process and the damage is not necessarily visible by classic means such as Trypan blue staining but becomes obvious in functional assays. Posln, sibly, the rather high spontaneous release seen :er in this study is also a result of the isolation pro--6 cedure, which may cause some kind of artificial In cellular 'leakage'. Alternatively, it could be bth caused by an in vivo stimulation of the cells. As ue the spontaneous leukotriene release seems to ise depend on the presence of inflammation, the lls site of tissue resection, and the kind of disease m of the donors, cell damage may be not the only Dn mediated by contaminating cells such as basophils, eosinophils or monocytes bearing the high affinity IL 3 receptor. Purified mast cell preparations are needed to study the mechanism of IL 3 effect on intestinal mast cell mediator release.
The mediator release in intestinal mast cells is subjected to a large variability, which is independent of the stimulus used for cell activation. This variability may be dependent on the presence of tissue inflammation, the kind of disease the donor suffers from, and yet unknown genetic factors. In this study, data from different patients were pooled together, which surely augment the variability. For example, Fig 5 shows that the presence of tissue inflammation in patients with inflammatory bowel disease is a relevant factor for the outcome of the release reaction. Previous studies showed, however, that a considerable ** variability of mediator release can be seen even in healthy persons. The phenomenon, which has been termed 'releasability', has been extensively studied in human basophils (reviewed in ref 3 [41] [42] [43] It is tempting to speculate that mast cells are also of importance in other inflammatory diseases of the intestine. It is questionable, however, whether such diseases are always IgE dependent. The definition of IgE independent mast cell agonists such as c-kit ligand or the recently described epithelial cell derived proteins44 capable of triggering mast cells for mediator release or enhancing the release reaction induced by other secretagogues may be of particular relevance for these disorders. Therefore, further studies are necessary to examine the expression of c-kit ligand and its receptor in disease, and to correlate these data with the in vivo release of mast cell mediators.
